82 studies found for:    PALO-10-20
Show Display Options
Rank Status Study
1 Completed
Has Results
Efficacy and Safety of Palonosetron Intravenous in Prevention of Chemotherapy Induced Nausea and Vomiting in Pediatric Patients
Condition: Chemotherapy-Induced Nausea and Vomiting
Interventions: Drug: Palonosetron;   Drug: Ondansetron;   Drug: Placebo to Ondansetron;   Drug: Placebo to Palonosetron
2 Recruiting Irinotecan Hydrochloride and Temozolomide With Temsirolimus or Monoclonal Antibody Ch14.18 in Treating Younger Patients With Refractory or Relapsed Neuroblastoma
Condition: Recurrent Neuroblastoma
Interventions: Drug: Temozolomide;   Drug: Irinotecan Hydrochloride;   Drug: Temsirolimus;   Biological: Monoclonal Antibody Ch14.18;   Biological: Sargramostim;   Other: Laboratory Biomarker Analysis
3 Active, not recruiting Paclitaxel or Polyglutamate Paclitaxel or Observation in Treating Patients With Stage III or Stage IV Ovarian Epithelial or Peritoneal Cancer or Fallopian Tube Cancer
Conditions: Malignant Ovarian Mixed Epithelial Tumor;   Ovarian Brenner Tumor;   Ovarian Clear Cell Cystadenocarcinoma;   Ovarian Endometrioid Adenocarcinoma;   Ovarian Mucinous Cystadenocarcinoma;   Ovarian Serous Cystadenocarcinoma;   Stage IIIA Fallopian Tube Cancer;   Stage IIIA Ovarian Cancer;   Stage IIIA Primary Peritoneal Cancer;   Stage IIIB Fallopian Tube Cancer;   Stage IIIB Ovarian Cancer;   Stage IIIB Primary Peritoneal Cancer;   Stage IIIC Fallopian Tube Cancer;   Stage IIIC Ovarian Cancer;   Stage IIIC Primary Peritoneal Cancer;   Stage IV Fallopian Tube Cancer;   Stage IV Ovarian Cancer;   Stage IV Primary Peritoneal Cancer;   Undifferentiated Ovarian Carcinoma
Interventions: Drug: Paclitaxel Poliglumex;   Other: Clinical Observation;   Drug: Paclitaxel
4 Recruiting Isotretinoin With or Without Dinutuximab, Aldesleukin, and Sargramostim Following Stem Cell Transplant in Treating Patients With Neuroblastoma
Conditions: Localized Resectable Neuroblastoma;   Localized Unresectable Neuroblastoma;   Regional Neuroblastoma;   Stage 4 Neuroblastoma;   Stage 4S Neuroblastoma
Interventions: Drug: Isotretinoin;   Biological: Sargramostim;   Biological: Monoclonal Antibody Ch14.18;   Biological: Aldesleukin;   Other: Laboratory Biomarker Analysis;   Other: Quality-of-Life Assessment;   Other: Pharmacological Study
5 Recruiting Study To Assess the Safety and Tolerability of Single Ascending Oral Doses of PBF-999 in Healthy Young Male Volunteers
Condition: Huntington's Disease
Interventions: Drug: PBF-999;   Drug: Placebo
6 Recruiting Safety and Efficacy of GS-4774 in Combination With Tenofovir Disoproxil Fumarate (TDF) for the Treatment of Subjects With Chronic Hepatitis B and Who Are Currently Not on Treatment
Condition: Chronic Hepatitis B
Interventions: Drug: TDF;   Biological: GS-4774
7 Completed Study to Assess the Safety, Tolerability and Pharmacokinetic Profile of PBF-680 After Multiple Oral Doses" in Healthy Volunteers.
Condition: Asthma
Interventions: Drug: PBF-680;   Drug: Placebo
8 Completed
Has Results
A Safety and Efficacy Study of LymphoStat-B™ (Monoclonal Anti-BLyS Antibody) in Subjects With Rheumatoid Arthritis (RA)
Condition: Arthritis, Rheumatoid
Interventions: Drug: Placebo;   Drug: Belimumab 1 mg/kg;   Drug: Belimumab 4 mg/kg;   Drug: Belimumab 10 mg/kg
9 Terminated
Has Results
Study of Apremilast to Evaluate the Safety and Effectiveness for Patients With Rheumatoid Arthritis
Condition: Rheumatoid Arthritis
Interventions: Drug: Apremilast 30 mg;   Drug: Apremilast 20 mg;   Drug: Placebo
10 Completed
Has Results
A Study Comparing 2 Doses Of CP-690,550 Vs. Placebo For The Treatment Of Rheumatoid Arthritis In Patients On Other Background Arthritis Medications
Condition: Arthritis, Rheumatoid
Interventions: Drug: CP-690,550;   Drug: Placebo
11 Completed
Has Results
A Phase 2 Study For Patients With A Physician's Diagnosis Of Rheumatoid Arthritis
Condition: Arthritis, Rheumatoid
Interventions: Drug: Adalimumab;   Drug: CP-690-550;   Drug: CP-690,550;   Drug: Placebo
12 Active, not recruiting Bipolar Maintenance Study of Lurasidone Adjunctive to Lithium or Divalproex
Condition: Bipolar I Disorder
Interventions: Drug: Lurasidone;   Drug: Placebo
13 Terminated
Has Results
Safety and Efficacy of Abatacept Versus Placebo in Participants With Psoriatic Arthritis
Condition: Psoriatic Arthritis
Interventions: Drug: Abatacept;   Drug: Placebo
14 Active, not recruiting Study to Investigate Idelalisib in Combination With Chemotherapeutic Agents, Immunomodulatory Agents and Anti-CD20 Monoclonal Antibody (mAb) in Subjects With Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma, Mantle Cell Lymphoma or Chronic Lymphocytic Leukemia
Conditions: Indolent Non-Hodgkin's Lymphoma;   Chronic Lymphocytic Leukemia;   Mantle Cell Lymphoma
Interventions: Drug: Idelalisib;   Drug: Rituximab;   Drug: Bendamustine;   Drug: Ofatumumab;   Drug: Fludarabine;   Drug: Everolimus;   Drug: Bortezomib;   Drug: Chlorambucil;   Drug: Lenalidomide
15 Completed Major Depressive Disorder (MDD) With Mixed Features - Flexible Dose
Condition: Major Depressive Disorder With Mixed Features
Interventions: Drug: Lurasidone;   Drug: Placebo
16 Completed Combination Chemotherapy in Treating Children With Newly Diagnosed Acute Lymphoblastic Leukemia
Condition: Leukemia
Interventions: Drug: cyclophosphamide;   Drug: cytarabine;   Drug: daunorubicin hydrochloride;   Drug: dexamethasone;   Drug: leucovorin calcium;   Drug: mercaptopurine;   Drug: methotrexate;   Drug: pegaspargase;   Drug: thioguanine;   Drug: vincristine sulfate
17 Active, not recruiting Doxorubicin Hydrochloride, Cyclophosphamide, and Paclitaxel With or Without Bevacizumab in Treating Patients With Lymph Node-Positive or High-Risk, Lymph Node-Negative Breast Cancer
Conditions: Estrogen Receptor Negative;   Estrogen Receptor Positive;   HER2/Neu Negative;   Male Breast Carcinoma;   Stage IA Breast Cancer;   Stage IB Breast Cancer;   Stage IIA Breast Cancer;   Stage IIB Breast Cancer;   Stage IIIA Breast Cancer;   Stage IIIB Breast Cancer;   Stage IIIC Breast Cancer
Interventions: Drug: Doxorubicin Hydrochloride;   Drug: Cyclophosphamide;   Drug: Paclitaxel;   Biological: Bevacizumab;   Other: Placebo;   Other: Laboratory Biomarker Analysis;   Other: Quality-of-Life Assessment
18 Completed Multi-dose Pharmacokinetics and Dose Ranging of Inositol in Premature Infants (INS-2)
Conditions: Infant, Newborn;   Infant, Low Birth Weight;   Infant, Small for Gestational Age;   Infant, Premature;   Retinopathy of Prematurity;   Bronchopulmonary Dysplasia (BPD)
Interventions: Drug: Inositol lower volume;   Drug: Inositol mid-level volume;   Drug: Inositol high volume;   Drug: Placebo low volume
19 Active, not recruiting
Has Results
Rituximab and Combination Chemotherapy in Treating Patients With Stage II, Stage III, or Stage IV Diffuse Large B-Cell Non-Hodgkin's Lymphoma
Condition: Lymphoma
Interventions: Biological: filgrastim;   Biological: rituximab;   Drug: carboplatin;   Drug: cyclophosphamide;   Drug: doxorubicin hydrochloride;   Drug: etoposide;   Drug: ifosfamide;   Drug: prednisone;   Drug: vincristine
20 Completed Safety and Efficacy Study of Ad2/Hypoxia Inducible Factor (HIF)-1α/VP16 Gene Transfer in Patients With Intermittent Claudication
Conditions: Intermittent Claudication;   Peripheral Vascular Disease;   Atherosclerosis
Interventions: Biological: Ad2/HIF-1α/VP16;   Other: Saline (Placebo Control)

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years